Marco Moreira

Inserm — France

Medicine · Health Sciences

9h-index2.4kcitations14works16.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal cell carcinoma treatment(5), Renal and related cancers(4), Cancer Immunotherapy and Biomarkers(3), Cancer Genomics and Diagnostics(3), Immune cells in cancer(3)

Publications14 total

Induced pluripotent stem cell-derived macrophages as a platform for modelling human disease
Nature reviews. Immunology·2024· 16 cited
Multicellular tumor spheroid model to study the multifaceted role of tumor-associated macrophages in PDAC
Drug Delivery and Translational Research·2023· 8 citedOpen Access
iPS-cell-derived microglia promote brain organoid maturation via cholesterol transfer
Nature·2023· 173 cited
Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial
The Lancet Oncology·2022· 128 citedOpen Access
Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors
The Oncologist·2022· 53 citedOpen Access
Immune-desert tumor microenvironment in SMARCA4-deficient thoracic sarcomas with limited efficacy of immune checkpoint inhibitors.
Journal of Clinical Oncology·2021· 1 cited
Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC)
Cancers·2021· 64 citedOpen Access
Impact des signatures moléculaires sur le choix du traitement systémique du cancer du rein métastatique
Bulletin du Cancer·2020· 5 cited
BIONIKK: A phase 2 biomarker driven trial with nivolumab and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naïve metastatic kidney cancer
Bulletin du Cancer·2020· 41 cited
Tertiary Lymphoid Structures and B cells: Clinical impact and therapeutic modulation in cancer
Seminars in Immunology·2020· 73 citedOpen Access
B cells are associated with survival and immunotherapy response in sarcoma
Nature·2020· 1.8k citedOpen Access
https://cdrjournal.com/article/view/3531
Cancer Drug Resistance·2020· 17 citedOpen Access
457: Diversity of methylation patterns in HPV16 LCR in cervical cancer
European Journal of Cancer·2014· 1 cited
Prevalence of BRCA1 and BRCA2 founder mutations in Brazilian hereditary breast and ovarian cancer families
Journal of Clinical Oncology·2008· 2 cited

Frequent Co-authors

Cheng‐Ming Sun(5), Catherine Sautès‐Fridman(5), Wolf H. Fridman(5), Yann Vano(5), Stéphane Oudard(5), Antoine Bougoüin(4), Audrey Simonaggio(4), Nicolas Epaillard(4), Guillaume Lacroix(3), Florent Ginhoux(3), Réza Elaidi(3), Florent Petitprez(2), Tom Wei‐Wu Chen(2), Satish Kumar Tiwari(2), Garett Dunsmore(2), Wei Jie Wong(2), Claudia Pasqualini(2), E. Braychenko(2), Maxime Meylan(2), Cédric Pobel(2)